These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

468 related items for PubMed ID: 16914074

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Metformin and pioglitazone: Effectively treating insulin resistance.
    Staels B.
    Curr Med Res Opin; 2006; 22 Suppl 2():S27-37. PubMed ID: 16914073
    [Abstract] [Full Text] [Related]

  • 3. Pioglitazone plus glimepiride: a promising alternative in metabolic control.
    Derosa G.
    Int J Clin Pract Suppl; 2007 Jun; (153):28-36. PubMed ID: 17594391
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Long-term therapy with addition of pioglitazone to metformin compared with the addition of gliclazide to metformin in patients with type 2 diabetes: a randomized, comparative study.
    Matthews DR, Charbonnel BH, Hanefeld M, Brunetti P, Schernthaner G.
    Diabetes Metab Res Rev; 2005 Jun; 21(2):167-74. PubMed ID: 15386821
    [Abstract] [Full Text] [Related]

  • 9. Direct comparison among oral hypoglycemic agents and their association with insulin resistance evaluated by euglycemic hyperinsulinemic clamp: the 60's study.
    Derosa G, Maffioli P, Salvadeo SA, Ferrari I, Gravina A, Mereu R, Palumbo I, D'Angelo A, Cicero AF.
    Metabolism; 2009 Aug; 58(8):1059-66. PubMed ID: 19394976
    [Abstract] [Full Text] [Related]

  • 10. Sitagliptin: a novel drug for the treatment of type 2 diabetes.
    Choy M, Lam S.
    Cardiol Rev; 2007 Aug; 15(5):264-71. PubMed ID: 17700385
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Thiazolidinediones in type 2 diabetes: a cardiology perspective.
    Khanderia U, Pop-Busui R, Eagle KA.
    Ann Pharmacother; 2008 Oct; 42(10):1466-74. PubMed ID: 18698014
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Thiazolidinediones: effects on the development and progression of type 2 diabetes and associated vascular complications.
    Krentz A.
    Diabetes Metab Res Rev; 2009 Feb; 25(2):112-26. PubMed ID: 19219860
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Comparison of the effects of pioglitazone and metformin on hepatic and extra-hepatic insulin action in people with type 2 diabetes.
    Basu R, Shah P, Basu A, Norby B, Dicke B, Chandramouli V, Cohen O, Landau BR, Rizza RA.
    Diabetes; 2008 Jan; 57(1):24-31. PubMed ID: 17914032
    [Abstract] [Full Text] [Related]

  • 18. Implications of rosiglitazone and pioglitazone on cardiovascular risk in patients with type 2 diabetes mellitus.
    Irons BK, Greene RS, Mazzolini TA, Edwards KL, Sleeper RB.
    Pharmacotherapy; 2006 Feb; 26(2):168-81. PubMed ID: 16466323
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.